ATE305473T1 - Pdgf-rezeptor-kinase hemmende verbindungen, deren herstellung, reinigung und diese verbindungen enthaltende pharmazeutische zusammensetzungen - Google Patents
Pdgf-rezeptor-kinase hemmende verbindungen, deren herstellung, reinigung und diese verbindungen enthaltende pharmazeutische zusammensetzungenInfo
- Publication number
- ATE305473T1 ATE305473T1 AT00973192T AT00973192T ATE305473T1 AT E305473 T1 ATE305473 T1 AT E305473T1 AT 00973192 T AT00973192 T AT 00973192T AT 00973192 T AT00973192 T AT 00973192T AT E305473 T1 ATE305473 T1 AT E305473T1
- Authority
- AT
- Austria
- Prior art keywords
- compounds
- purification
- preparation
- pharmaceutical compositions
- compositions containing
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US09/436,651 US6358954B1 (en) | 1999-11-09 | 1999-11-09 | PDGF receptor kinase inhibitory compounds, their preparation, purification and pharmaceutical compositions including same |
PCT/IL2000/000709 WO2001034607A1 (en) | 1999-11-09 | 2000-11-02 | Pdgf receptor kinase inhibitory compounds, their preparation, purification and pharmaceutical compositions including same |
Publications (1)
Publication Number | Publication Date |
---|---|
ATE305473T1 true ATE305473T1 (de) | 2005-10-15 |
Family
ID=23733269
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT00973192T ATE305473T1 (de) | 1999-11-09 | 2000-11-02 | Pdgf-rezeptor-kinase hemmende verbindungen, deren herstellung, reinigung und diese verbindungen enthaltende pharmazeutische zusammensetzungen |
Country Status (9)
Country | Link |
---|---|
US (3) | US6358954B1 (de) |
EP (1) | EP1228072B1 (de) |
JP (1) | JP2003513978A (de) |
AT (1) | ATE305473T1 (de) |
AU (1) | AU781871B2 (de) |
CA (1) | CA2387624A1 (de) |
DE (1) | DE60022895T2 (de) |
ES (1) | ES2251407T3 (de) |
WO (1) | WO2001034607A1 (de) |
Families Citing this family (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6358954B1 (en) * | 1999-11-09 | 2002-03-19 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | PDGF receptor kinase inhibitory compounds, their preparation, purification and pharmaceutical compositions including same |
US6433018B1 (en) * | 2001-08-31 | 2002-08-13 | The Research Foundation Of State University Of New York | Method for reducing hypertrophy and ischemia |
WO2003086404A1 (en) | 2002-04-08 | 2003-10-23 | Merck & Co., Inc. | Fused quinoxaline derivatives as inhibitors of akt activity |
IL164799A0 (en) | 2002-04-25 | 2005-12-18 | Univ Connecticut | Using heat shock proteins to improve the therapeutic benefit of a non-vaccine treatment modality |
ES2388138T3 (es) | 2003-08-27 | 2012-10-09 | Ophthotech Corporation | Terapia de combinación para tratamiento de trastornos neovasculares oculares |
EP2125895B1 (de) * | 2007-02-02 | 2015-04-08 | Vegenics Pty Ltd | Vegf-rezeptorantagonisten zur behandlung von allommunität bei organtransplantationen und atherosklerose |
US8093236B2 (en) * | 2007-03-13 | 2012-01-10 | Takeda Pharmaceuticals Company Limited | Weekly administration of dipeptidyl peptidase inhibitors |
US10842669B2 (en) | 2008-11-13 | 2020-11-24 | Gholam A. Peyman | Ophthalmic drug delivery method |
US20110125090A1 (en) * | 2008-11-13 | 2011-05-26 | Peyman Gholam A | Ophthalmic drug delivery system and method |
US10272035B2 (en) | 2008-11-13 | 2019-04-30 | Gholam A. Peyman | Ophthalmic drug delivery method |
WO2010075282A1 (en) * | 2008-12-22 | 2010-07-01 | University Of Washington | Molecular inhibitors of the wnt/beta-catenin pathway |
US20120189641A1 (en) | 2009-02-25 | 2012-07-26 | OSI Pharmaceuticals, LLC | Combination anti-cancer therapy |
WO2010099363A1 (en) | 2009-02-27 | 2010-09-02 | Osi Pharmaceuticals, Inc. | Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation |
JP2012519282A (ja) | 2009-02-27 | 2012-08-23 | オーエスアイ・ファーマシューティカルズ,エルエルシー | 間葉様腫瘍細胞またはその生成を阻害する薬剤を同定するための方法 |
WO2010099138A2 (en) | 2009-02-27 | 2010-09-02 | Osi Pharmaceuticals, Inc. | Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation |
US9072741B2 (en) * | 2009-10-08 | 2015-07-07 | The General Hospital Corporation | Methods of treating liver fibrosis and pre-cirrhosis with epidermal growth factor receptor inhibitors |
CN103327978A (zh) * | 2010-10-08 | 2013-09-25 | 总医院公司 | 用表皮生长因子受体抑制剂治疗肝纤维化和前肝硬化的方法 |
WO2012149014A1 (en) | 2011-04-25 | 2012-11-01 | OSI Pharmaceuticals, LLC | Use of emt gene signatures in cancer drug discovery, diagnostics, and treatment |
WO2013152252A1 (en) | 2012-04-06 | 2013-10-10 | OSI Pharmaceuticals, LLC | Combination anti-cancer therapy |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4304846A (en) * | 1979-02-09 | 1981-12-08 | Ciba-Geigy Ag | Method for processing silver dye-bleach materials |
DE3701277A1 (de) * | 1987-01-17 | 1988-07-28 | Boehringer Mannheim Gmbh | Neue tricyclische benzimidazole, verfahren zu ihrer herstellung und verwendung als arzneimittel |
US5171217A (en) * | 1991-02-28 | 1992-12-15 | Indiana University Foundation | Method for delivery of smooth muscle cell inhibitors |
CA2148082A1 (en) * | 1993-09-03 | 1995-03-09 | Daisuke Machii | Imidazoquinazoline derivatives |
WO1996029331A1 (de) * | 1995-03-20 | 1996-09-26 | Dr. Karl Thomae Gmbh | Imidazochinazoline, diese verbindungen enthaltende arzneimittel, deren verwendung und verfahren zu ihrer herstellung |
WO1998008848A1 (fr) * | 1996-08-30 | 1998-03-05 | Kyowa Hakko Kogyo Co., Ltd. | Derives d'imidazoquinazoline |
WO1999007701A1 (en) | 1997-08-05 | 1999-02-18 | Sugen, Inc. | Tricyclic quinoxaline derivatives as protein tyrosine kinase inhibitors |
US5990146A (en) * | 1997-08-20 | 1999-11-23 | Warner-Lambert Company | Benzimidazoles for inhibiting protein tyrosine kinase mediated cellular proliferation |
US5932580A (en) * | 1997-12-01 | 1999-08-03 | Yissum Research And Development Company Of The Hebrew University Of Jerusalem | PDGF receptor kinase inhibitory compounds their preparation and compositions |
SE9800835D0 (sv) * | 1998-03-13 | 1998-03-13 | Astra Ab | New Compounds |
WO1999053924A1 (fr) * | 1998-04-17 | 1999-10-28 | Kyowa Hakko Kogyo Co., Ltd. | Agent analgesique |
US6358954B1 (en) * | 1999-11-09 | 2002-03-19 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | PDGF receptor kinase inhibitory compounds, their preparation, purification and pharmaceutical compositions including same |
-
1999
- 1999-11-09 US US09/436,651 patent/US6358954B1/en not_active Expired - Fee Related
-
2000
- 2000-11-02 ES ES00973192T patent/ES2251407T3/es not_active Expired - Lifetime
- 2000-11-02 EP EP00973192A patent/EP1228072B1/de not_active Expired - Lifetime
- 2000-11-02 WO PCT/IL2000/000709 patent/WO2001034607A1/en active IP Right Grant
- 2000-11-02 AT AT00973192T patent/ATE305473T1/de not_active IP Right Cessation
- 2000-11-02 JP JP2001536554A patent/JP2003513978A/ja not_active Abandoned
- 2000-11-02 CA CA002387624A patent/CA2387624A1/en not_active Abandoned
- 2000-11-02 DE DE60022895T patent/DE60022895T2/de not_active Expired - Fee Related
- 2000-11-02 AU AU11730/01A patent/AU781871B2/en not_active Ceased
-
2001
- 2001-04-09 US US09/828,602 patent/US6673798B2/en not_active Expired - Fee Related
-
2003
- 2003-11-19 US US10/715,547 patent/US20040132725A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
JP2003513978A (ja) | 2003-04-15 |
AU1173001A (en) | 2001-06-06 |
EP1228072A1 (de) | 2002-08-07 |
WO2001034607A1 (en) | 2001-05-17 |
DE60022895D1 (de) | 2006-02-09 |
US20020028817A1 (en) | 2002-03-07 |
US20040132725A1 (en) | 2004-07-08 |
AU781871B2 (en) | 2005-06-16 |
US6358954B1 (en) | 2002-03-19 |
CA2387624A1 (en) | 2001-05-17 |
DE60022895T2 (de) | 2006-08-24 |
US6673798B2 (en) | 2004-01-06 |
ES2251407T3 (es) | 2006-05-01 |
EP1228072A4 (de) | 2003-05-07 |
EP1228072B1 (de) | 2005-09-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ATE305473T1 (de) | Pdgf-rezeptor-kinase hemmende verbindungen, deren herstellung, reinigung und diese verbindungen enthaltende pharmazeutische zusammensetzungen | |
ATE232862T1 (de) | Oxazolidinon derivate und diese enthaltende pharmazeutische zusammensetzungen | |
TR199801530T2 (xx) | VEGF �nhibit�rleri olarak kinazolin t�revleri. | |
GEP20033131B (en) | Azabicycloalkanes as CCR5 Modulators, Pharmaceutical Compositions Containing the Same and Their Use for Treatment and Prevention of Diseases Caused by CCR5 Activity | |
HUP0004040A1 (hu) | Antimikrobiális hatású pleuromutilinszármazékok, eljárás ezek előállítására, ezeket tartalmazó gyógyászati készítmények és alkalmazásuk | |
ATE154354T1 (de) | Azabicyclische verbindungen, diese enthaltende pharmazeutische zubereitungen und ihre therapeutische verwendung | |
DE50108674D1 (de) | Verbindungen mit einer sulfonamidgruppe und diese verbindungen enthaltende pharmazeutische zusammensetzungen | |
PT928788E (pt) | Compostos farmaceuticamente activos | |
NO996108L (no) | 9-oksinerytromycinderivater | |
DK0583421T3 (da) | Substituerede dibenzoxazepinforbindelser, lægemidler og fremgangsmåder til anvendelse | |
ATE110071T1 (de) | Pyridazinon-derivate und diese enthaltende pharmazeutische zubereitungen. | |
WO2003063787A3 (en) | Non-steroidal analogs of 2-methoxyestradiol | |
ATE233754T1 (de) | Diphenyl-piperidin derivate | |
UA42733C2 (uk) | Похідні біснафталіміду та їх фармацевтично прийнятні кислотно-адитивні солі, фармацевтична композиція з цитотоксичною активністю, яка їх містить | |
TR199801229T2 (xx) | ''Metalopeptidaz inhibisyon aktivitesini havi tiol t�revleri | |
FR2707638B1 (fr) | Nouveaux dérivés d'amino-acides, leurs procédés de préparation et leur application thérapeutique. | |
ATE250610T1 (de) | Kaliumkanal-blockierende mittel | |
PT991409E (pt) | Composicoes farmaceuticas de libertacao controlada contendo tiagabina | |
AP9801235A0 (en) | Erythromycin derivatives. | |
YU46302A (sh) | Supstituisani piroli | |
YU25202A (sh) | Supstituisani piroli kao antiproliferativna sredstva za lečenje kancera | |
WO2001007029A3 (en) | Substituted guanidines and the use thereof | |
BRPI0415546A (pt) | composto, composição farmacêutica, uso de um composto, e, métodos de tratamento ou profilaxia de doenças ou condições humanas, e de distúrbios | |
DE69528984T2 (de) | Hemmung der leukotrienbiosynthese mittels harnstoffderivaten | |
TH23898A (th) | วิธีการหยุดยั้งการออกฤทธิ์ของ il-6 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |